Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
OBJECTIVE
To evaluate long-term results of low-fluence photodynamic therapy (PDT) with verteporfin in the treatment of chronic central serous chorioretinopathy (CCSC).


METHODS
Retrospective medical record review of 38 eyes (34 patients) who received low-fluence PDT for the treatment of CCSC. Visual acuity (VA), fundus biomicroscopy, fluorescein angiography (FA), indocyanine green angiography (ICG) and optical coherence tomography (OCT) were analyzed.


RESULTS
Thirty-eight eyes (34 patients) with CCSC received low-fluence PDT. Mean follow-up after PDT was 43.97 months. Mean logMar best corrected VA (BCVA) improved significantly from 0.33 to 0.11 at the last follow-up which corresponds to a gain of 2.2 lines. At 3 months, complete resolution of central subretinal fluid was achieved on OCT after 1 PDT in 37 eyes and after 2 PDTs in 1 eye (retreated at 3 months after first PDT). One patient developed choroidal neovascularization (CNV) 4 years after his low-fluence PDT and received anti-vascular endothelial growth factor (VEGF) injections.


CONCLUSIONS
Low-fluence PDT with verteporfin for CCSC seems efficacious and safe in the long-term.
Brugmann university hospital, ophthalmology department, place Arthur Van Gehuchten 4, 1020 Brussel, Belgium; Saint-Pierre university hospital, ophthalmology department, rue Haute, 322, 1000 Brussels, Belgium. Electronic address: Emmanuelle.leys2403@gmail.com.
E
E
Leys
Brugmann university hospital, ophthalmology department, place Arthur Van Gehuchten 4, 1020 Brussel, Belgium.
S
S
Tuttle
Erasme university hospital, ophthalmology department, 808, route de Lennik, 1070 Brussels, Belgium.
F
F
Rasquin
Erasme university hospital, ophthalmology department, 808, route de Lennik, 1070 Brussels, Belgium.
F
F
Neu
Brugmann university hospital, ophthalmology department, place Arthur Van Gehuchten 4, 1020 Brussel, Belgium.
L
L
Postelmans
D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin
Choriorétinite séreuse centrale chronique; Choroidal vascular hyperpermeability; Chronic central serous chorioretinopathy; Décollement séreux rétinien; Fluence réduite; Hyperperméabilité choroïdienne; Low-fluence; Macular neurosensory detachment; Photodynamic therapy; Photothérapie dynamique; Serous retinal detachment; Verteporfin; Vertéporfine